Does pharma sprinkle “commercially sensitive information” into drug protocol docs to later block public access to efficacy and safety data? Or is their “commercially sensitive” claim pure fiction?

This recent blog posts shows how pharma gets drug regulators to cover for them when it comes to freedom of information requests–requests that can benefit the public and improve personal decision making regarding healthcare choices. “Common sense suggests drug company commercial interests should never over-ride patient welfare.” Read more at https://davidhealy.org/secret-moderna-trial-documents/.